Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Depreciation & Amortization (CF): 2020-2024

Historic Depreciation & Amortization (CF) for ARS Pharmaceuticals (SPRY) over the last 5 years, with Dec 2024 value amounting to $100,000.

  • ARS Pharmaceuticals' Depreciation & Amortization (CF) rose 291.00% to $391,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year increase of 609.22%. This contributed to the annual value of $100,000 for FY2024, which is negligibly% changed negligibly from last year.
  • ARS Pharmaceuticals' Depreciation & Amortization (CF) amounted to $100,000 in FY2024, which was down 0.00% from $100,000 recorded in FY2023.
  • In the past 5 years, ARS Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $637,000 in FY2020 and a low of $100,000 during FY2022.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $100,000 (2024), whereas its average is $100,000.
  • Data for ARS Pharmaceuticals' Depreciation & Amortization (CF) shows a maximum YoY crashed of 66.56% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows ARS Pharmaceuticals' Depreciation & Amortization (CF) stood at $637,000 in 2020, then slumped by 66.56% to $213,000 in 2021, then plummeted by 53.05% to $100,000 in 2022, then remained steady at $100,000 in 2023, then remained steady at $100,000 in 2024.